Objective      To compare the efficacy of 5 kinds of platinum-based chemotherapy regimens in the first-line treatment of advanced non-small cell lung cancer (NSCLC)

and to further explore the possible ways to improve the prognosis.       Methods      A retrospective study was conducted and included the clinical data of 352 patients (mean age 59) with stage Ⅲ and Ⅳ NSCLC. The patients received the third generation new drug-based platinum r

egimens

including 5 kinds of regimens

TP

DP

LP

GP

and PP. The primary endpoint was objective response rate (ORR)

disease control rate (DCR)

progression-free survival (PFS) and overall survival (OS).       Results      The overall objective response rate was 36.36% and disease control rate was 69.03%. The median PFS was 7 months and the median OS was 13 months. There was no statistically significant difference in ORR

DCR

PFS

and OS among the 5 groups (

P

0.05). The incidence of grade 3 to 4 hematologic toxicity was significantly higher in the patients received TP regimens (

P

0.05). Stratified analysis showed that age and pathology perhaps guide preferential treatment. COX model regression analysis showed that ECOG PS

tumor stage

chemotherapy cycles

objective response rate

disease control rate and second-line chemotherapy had independent prognostic significance (

P

0.05)

but sex

age

pathology types and smoking had not.       Conclusion      The efficacy of the 5 platinum-based chemotherapy regimens in the treatment of NSCLC does not show any statistical difference. The incidence of grade 3 to 4 hematologic toxicity is significantly higher in the patients received TP regimen. The ECOG PS

tumor stage

chemotherapy cycles

effect after first-line chemotherapy and second-line chemotherapy are of independent prognostic significance.